Results 11 to 20 of about 3,389 (131)

Development of a Practical Manufacturing Process to Relebactam via Thorough Understanding of the Origin and Control of Oligomeric Impurities

open access: yes, 2021
The development of a robust manufacturing process to relebactam, a potent β-lactamase inhibitor, is described. The origin and control strategy of oligomer impurities formed during hydrogenolysis of benzyl urea intermediate 9 and deprotection of Boc ...
Marco Euclide Armenante (11525068)   +37 more
core   +1 more source

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase

open access: yes, 2023
Background: Ceftazidime-avibactam was approved by the FDA to treat infections caused by Enterobacterales carrying blaKPC-2. However, variants of KPC-2 with amino acid substitutions at position 179 have emerged and confer resistance to ceftazidime ...
Krisztina M. Papp-Wallace   +7 more
core   +1 more source

Relebactam is a potent inhibitor of the kpc-2 -lactamase and restores imipenem susceptibility in kpc-producing enterobacteriaceae [PDF]

open access: yes, 2018
The imipenem-relebactam combination is in development as a potential treatment regimen for infections caused by Enterobacteriaceae possessing complex -lactamase backgrounds. Relebactam is a -lactamase inhibitor that possesses the diazabicyclooctane core,
Alsop J.   +9 more
core   +1 more source

Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae

open access: yes, 2017
We determined imipenem, imipenem-relebactam, ceftazidime, and ceftazidime-avibactam MICs against 100 CRE isolates that underwent whole-genome sequencing.
Palash Samanta   +6 more
core   +1 more source

Assessing kidney function for drug dosing in critical illness

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Kidney‐function assessment supports drug dosing in critical illness but does not directly measure drug clearance. Reduced creatinine generation, fluid shifts and rapidly changing filtration can make creatinine‐based estimates misleading, whereas genuinely augmented renal clearance can cause insufficient drug exposure. These processes can coexist.
Ming‐Shen Lin, Kuo‐Fan Liao
wiley   +1 more source

Increased bla(KPC) Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate

open access: yes, 2022
Herein, we report the in vivo evolution of imipenem/relebactam-resistance in KPC-producing K. pneumoniae (KPC-Kp) isolated from a critically-ill patient treated with multiple combination therapies based on ceftazidime-avibactam or meropenem-vaborbactam ...
Boattini, Matteo   +5 more
core   +1 more source

Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi   +4 more
wiley   +1 more source

RESTORE-IMI 1: A Multicenter, Randomized, Doubleblind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections [PDF]

open access: yes, 2019
Background. The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections. Methods.
Du, Jiejun   +35 more
core   +1 more source

Rapid detection of KPC-producing Enterobacterales by using a modified Carba NP test with imipenem/relebactam.

open access: yes, 2022
20.500.12530/87858Here, we propose a novel modified Carba NP test for detecting KPC-producing Enterobacterales using imipenem/relebactam. The test performance was evaluated in a random selection of 160 previously molecularly characterized clinical ...
González-Bardanca, Mónica   +4 more
core   +1 more source

In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies) [PDF]

open access: yes, 2022
[Objectives] To study the in vitro activity of imipenem/relebactam and comparators and the imipenem/relebactam resistance mechanisms in a Pseudomonas aeruginosa collection from Portugal (STEP, 2017-18) and Spain (SUPERIOR, 2016-17) surveillance studies ...
Vieira, Ana Raquel   +28 more
core   +1 more source

Home - About - Disclaimer - Privacy